- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | AEON Biopharma regains NYSE American listing compliance after $13.6M offering | 1 | Seeking Alpha | ||
| Mo | AEON Biopharma Inc: AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards | 89 | GlobeNewswire (Europe) | ALISO VIEJO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX... ► Artikel lesen | |
| 23.07. | AEON Biopharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 15.07. | AEON Biopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.07. | AEON Biopharma prices $13.75M offering with milestone warrants | 1 | Seeking Alpha | ||
| 14.07. | AEON Biopharma Inc: AEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding | 167 | GlobeNewswire (Europe) | IRVINE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA)... ► Artikel lesen | |
| 09.07. | AEON Biopharma, Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 08.07. | AEON Biopharma, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| AEON BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 17.06. | AEON Biopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.06. | AEON Biopharma Inc: AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX at the 68th Annual Scientific Meeting of the American Headache Society | 2 | GlobeNewswire (USA) | ||
| 15.05. | AEON Biopharma-Aktie fällt nach Quartalsverlust um über 2 % | 1 | Investing.com Deutsch | ||
| 15.05. | AEON Biopharma GAAP EPS of -$0.29 | 1 | Seeking Alpha | ||
| 14.05. | AEON Biopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 24.04. | AEON Biopharma Inc: AEON Biopharma Sets Annual Shareholder Meeting | 3 | GlobeNewswire (USA) | ||
| 03.04. | AEON Biopharma Inc: AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards | 492 | GlobeNewswire (Europe) | IRVINE, Calif., April 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar... ► Artikel lesen | |
| 03.04. | AEON Biopharma Inc: AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 | 1 | GlobeNewswire (USA) | ||
| 03.04. | AEON Biopharma receives additional NYSE American non-compliance notice | 2 | Seeking Alpha | ||
| 30.03. | AEON Biopharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 30.03. | AEON Biopharma reports biosimilar progress, secures financing | 1 | Investing.com | ||
| 30.03. | AEON Biopharma Inc: AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program | 265 | GlobeNewswire (Europe) | - Announced positive initial comparative analytical results, confirming identical amino-acid sequencing and highly similar functional characteristics to BOTOX - - Reported positive FDA BPD Type 2a... ► Artikel lesen |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 45,180 | +0,30 % | BTIG cuts Tempus AI stock price target to $70 on model update | ||
| ABIVAX | 113,90 | +3,64 % | EQS-News: ABIVAX: Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod | EQS-News: ABIVAX
/ Key word(s): Regulatory Admission
Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod
30.07.2026 / 22:05 CET/CEST
The issuer... ► Artikel lesen | |
| ALTERITY THERAPEUTICS | 0,302 | -0,66 % | ALTERITY THERAPEUTICS LIMITED: Alterity to Present at Canaccord Genuity Growth Conference | ||
| APTEVO THERAPEUTICS | 4,100 | 0,00 % | Aptevo Therapeutics: Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone | Filing supports potential development of radiopharmaceuticals, T-cell engagers and other immune-based approaches using a versatile platform approach SEATTLE, WA / ACCESS Newswire / July 27, 2026 / Aptevo... ► Artikel lesen | |
| BIOCURE TECHNOLOGY | 0,015 | -9,38 % | XFRA 1WH0: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 134,84 | 0,00 % | Laufende Fusionskontrollverfahren: AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USA | Datum der Anmeldung:07.07.2026Aktenzeichen:B3-76/26Unternehmen:AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USAProduktmärkte:Biotechnologie... ► Artikel lesen | |
| COGENT BIOSCIENCES | 42,390 | 0,00 % | If You Invested $100 In Cogent Biosciences Stock 5 Years Ago, You Would Have This Much Today | ||
| QIAGEN | 36,460 | +0,89 % | Ihre wichtigsten Termine: Frische Zahlen von Ebay, Eli Lill, Allstate, Infineon, Novo Nordisk, Walt Disney | Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine 06:45 Uhr, Deutschland: Basler... ► Artikel lesen | |
| RELAY THERAPEUTICS | 19,770 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates | Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine- sensitive patients expected to initiate in early 2027, subject to regulatory... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 361,08 | +0,09 % | Praxis Precision Medicines, Inc. - 10-Q, Quarterly Report | ||
| DYNE THERAPEUTICS | 26,250 | 0,00 % | PetAg expands Tractor Supply distribution of supplements, life-stage nutrition: The company's Dyne Soft Chews and Esbilac ... | ||
| BEAM THERAPEUTICS | 27,480 | 0,00 % | Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) | Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 Dosing Complete for All Adult and Adolescent Patients... ► Artikel lesen | |
| TANGO THERAPEUTICS | 27,040 | -0,11 % | Tango Therapeutics, Inc.: Tango Therapeutics Announces Executive Chair Transition | BOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 25,290 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| AMYLYX PHARMACEUTICALS | 22,820 | 0,00 % | Amylyx anticipates Phase III LUCIDITY top-line data in late August or early September with $250.8M cash runway into 2028 |
AEON BIOPHARMA INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,277 Euro und damit +0,69 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AEON BIOPHARMA INC finden Sie auf Wallstreet Online.